2022
In total, 40 patients have been administered and FG001 has been shown safe and well tolerated (please see table). No serious drug related...
KEY FINANCIAL FIGUES Q4 2021 Full Year 2021 (Audited) HIGHLIGHTS FROM 2021 Q1 Q2 Q3 Q4 HIGHLIGHTS AFTER THE PERIOD For further information...
29 March, 2022
FluoGuide A/S issue warrants to employees and management
Today, the Board of Directors of FluoGuide has exercised its authorization to issue new warrants by issuing 40,000 warrants to employees...
24 March, 2022
FluoGuide has received approval from the Danish Medicines Agency to initiate phase II trial with FG001 in lung cancer
Following approval from the Danish Medicines Agency and Ethical Committee, FluoGuide will initiate enrolment a phase II trial in lung...
The grant will accelerate the development of FG001 in the treatment of less malignant brain cancers to the benefit of more patients...
The board of directors of FluoGuide has, based on the authorization granted by the annual general meeting on 9 February 2021, and as...
10 March, 2022
FluoGuide intends to carry out a directed share issue of approximately SEK 25 million
The subscription price and the total number of new shares in the Directed Share Issue will be determined by way of an accelerated bookbuilding...
2021
22 December, 2021
FluoGuide has submitted a Clinical Trial Application (CTA) to the Danish Medicines Agency to initiate phase II trial with FG001 in lung cancer
Following approval from the Danish Medicines Agency, FluoGuide will initiate the phase II trial in lung cancer in collaboration with...
19 November, 2021
ABG Sundal Collier initiates equity research on FluoGuide
Starting today, ABG has initiated its equity research, meaning that ABG will continuously monitor and analyze FluoGuide’s operations...